FIELD: medicine.
SUBSTANCE: present invention relates to medicine and is a method for non-contact stimulation of the transcriptional activity of the CDKN1B gene. To implement the present invention, radiation of prostate tumor cells is carried out on a Novalis TX linear accelerator in a discrete pulse mode, 3 pulses of 6.4 Gy, the interval between pulses is 120 seconds, and the expression level of the CDKN1B, CDK2 and CDK1 genes is evaluated.
EFFECT: invention allows for the regulation of the cell cycle of prostate tumor cells by activating a cyclin-dependent kinase 2 inhibitor with preserved transcriptional activity of cyclin-dependent kinase 1.
5 cl, 4 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE RADIOSENSITIVITY OF MALIGNANT RECTAL TUMOURS | 2020 |
|
RU2754154C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSIS OF HIGH-GRADE SEROUS OVARIAN ADENOCARCINOMA BASED ON COPY INDEX OF SULT1E1, CYP1B1, AND ESR1 GENES | 2021 |
|
RU2750472C1 |
| ESSC-TIPE-1TEST-SYSTEM FOR MOLECULAR-GENETIC TYPING OF SQUAMOUS OESOPHAGEAL CANCER | 2020 |
|
RU2742468C1 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| MINIMALLY INVASIVE METHOD FOR DETECTING SENSITIVITY OF PROSTATE TUMOURS TO RADIATION THERAPY BASED ON CHANGE IN BRCA2 AND RAD50 GENE COPYING | 2019 |
|
RU2728428C1 |
| MINIMALLY INVASIVE METHOD FOR DIFFERENTIAL EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND FATTY HEPATOSIS | 2023 |
|
RU2822224C1 |
| TEST SYSTEM FOR DETERMINING IDH 1/2 GENE STATUS IN GLIAL TUMOR TISSUES | 2023 |
|
RU2823028C1 |
| COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HUMAN PROSTATE CANCER | 2002 |
|
RU2346685C2 |
| AGENTS ADJUSTING, INHIBITING OR MODULATING ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTORS (CTGF) AS UNIQUE DRUGS FOR INTRAOCULAR TENSION REDUCTION AND TREATMENT OF GLAUCOMA RETINOPATHIES/OPTICAL NEUROPATHIES | 2003 |
|
RU2332213C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANT TUMOUR | 2013 |
|
RU2660349C2 |
